MII IG Kerndatensatz-Modul Onkologie
2027.0.0-ballot.1 - Germany

This page is part of the MII IG Kerndatensatz-Modul Onkologie (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

: mii-exa-onko-tumorkonferenz-molekular

Raw xml | Download


<CarePlan xmlns="http://hl7.org/fhir">
  <id value="mii-exa-onko-tumorkonferenz-molekular"/>
  <meta>
    <profile
             value="https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/StructureDefinition/mii-pr-onko-tumorkonferenz|2027.0.0-ballot.1"/>
  </meta>
  <language value="en"/>
  <text>
    <status value="generated"/>
    <div xml:lang="en" lang="en"><hr/><p><b>English</b></p><hr/><p class="res-header-id"><b>Generated Narrative: CarePlan mii-exa-onko-tumorkonferenz-molekular</b></p><a name="mii-exa-onko-tumorkonferenz-molekular"> </a><a name="hcmii-exa-onko-tumorkonferenz-molekular"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-mii-pr-onko-tumorkonferenz.html">MII PR Onkologie Tumorkonferenz</a> version: 2027.0.0-ballot.1</p></div><p><b>status</b>: Active</p><p><b>intent</b>: Plan</p><p><b>category</b>: <span title="Codes:{https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-therapieplanung-typ praeth}">Molekulares Tumorboard</span></p><p><b>subject</b>: <a href="Patient-example.html">Erika Beispiel  Female, DoB: 1965-04-12</a></p><p><b>created</b>: 2024-01-15</p><p><b>addresses</b>: <a href="Condition-primaertumor-example.html">Condition Bösartige Neubildung: Brustdrüse, nicht näher bezeichnet</a></p><blockquote><p><b>activity</b></p><h3>Details</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Status</b></td><td><b>Description</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-therapie-typ ZS}">Zielgerichtete Anti-HER2 Therapie</span></td><td>Not Started</td><td>Basierend auf HER2-Amplifikation: Trastuzumab + Pertuzumab Kombination empfohlen</td></tr></table></blockquote><blockquote><p><b>activity</b></p><h3>Details</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Status</b></td><td><b>Description</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-therapie-typ CZ}">Chemotherapie + CDK4/6 Inhibitor</span></td><td>Not Started</td><td>Alternative basierend auf HR+/HER2- Status: Palbociclib + Letrozol</td></tr></table></blockquote><blockquote><p><b>activity</b></p><h3>Details</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Status</b></td><td><b>Description</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-therapie-typ ST}">Strahlentherapie</span></td><td>Not Started</td><td>Adjuvante Bestrahlung nach Operation</td></tr></table></blockquote></div>
  </text>
  <status value="active"/>
  <intent value="plan"/>
  <category>
    <coding>
      <system
              value="https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-therapieplanung-typ"/>
      <code value="praeth"/>
    </coding>
    <text value="Molekulares Tumorboard"/>
  </category>
  <subject>🔗 
    <reference value="Patient/example"/>
  </subject>
  <created value="2024-01-15"/>
  <addresses>🔗 
    <reference value="Condition/primaertumor-example"/>
  </addresses>
  <activity>
    <detail>
      <code>
        <coding>
          <system
                  value="https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-therapie-typ"/>
          <code value="ZS"/>
        </coding>
        <text value="Zielgerichtete Anti-HER2 Therapie"/>
      </code>
      <status value="not-started"/>
      <description
                   value="Basierend auf HER2-Amplifikation: Trastuzumab + Pertuzumab Kombination empfohlen"/>
    </detail>
  </activity>
  <activity>
    <detail>
      <code>
        <coding>
          <system
                  value="https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-therapie-typ"/>
          <code value="CZ"/>
        </coding>
        <text value="Chemotherapie + CDK4/6 Inhibitor"/>
      </code>
      <status value="not-started"/>
      <description
                   value="Alternative basierend auf HR+/HER2- Status: Palbociclib + Letrozol"/>
    </detail>
  </activity>
  <activity>
    <detail>
      <code>
        <coding>
          <system
                  value="https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-therapie-typ"/>
          <code value="ST"/>
        </coding>
        <text value="Strahlentherapie"/>
      </code>
      <status value="not-started"/>
      <description value="Adjuvante Bestrahlung nach Operation"/>
    </detail>
  </activity>
</CarePlan>